Survival and Disease Progression Benefits Seen Even in Patients Under 50 and Under 40
No Major Differences in Safety by Age Group; Results Presented as a Poster at ILCA 2026

The combination therapy of HLB's liver cancer drug candidates “Rivoceranib + Camrelizumab” has been shown to extend survival regardless of patient age.


HLB Liver Cancer Drug Shows Consistent Survival Benefit Across All Age Groups View original image

HLB’s U.S. subsidiary, Elevar Therapeutics, announced on the 1st that it will present additional age-group analysis results of the global Phase 3 clinical trial “CARES-310,” which targeted patients with unresectable hepatocellular carcinoma, in a poster at the International Liver Cancer Association (ILCA 2026) Annual Conference, held in Brussels, Belgium from September 3 to 5 (local time).


Among patients under the age of 50, those who received the combination therapy had a median survival period of 21.5 months, which was longer than the 15.2 months observed in the Sorafenib group, the standard treatment. The median progression-free survival was also longer at 5.5 months, compared to 2.7 months for those treated with Sorafenib.


In patients aged 50 and over, the median survival for those on the combination therapy was 23.9 months, longer than the 15.2 months observed in the Sorafenib group. The progression-free survival was 6.2 months, versus 3.7 months for the Sorafenib group.


This trend was also seen among younger patients under 40. The median survival for those receiving the combination therapy was 24.2 months, compared to 15.2 months in the Sorafenib group, and the progression-free survival was 5.5 months, compared to 2.2 months for Sorafenib.


Adverse events related to the treatment did not differ significantly by age group. Among severe side effects, high blood pressure was most commonly observed with the combination therapy, while hand-foot skin reactions were most common in the Sorafenib group.



Meanwhile, Elevar received a Complete Response Letter (CRL) from the FDA in July regarding the U.S. new drug application for the first-line treatment of liver cancer using the Rivoceranib and Camrelizumab combination therapy, due to manufacturing and quality control issues at its production facility. The company is currently proceeding with procedures to resubmit to the FDA.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing